PepGen presents EDO platform data for DM1 candidate PGN-EDODM1

PepGen Inc. released a May 2026 company presentation detailing clinical progress of its oligonucleotide therapy PGN-EDODM1 for myotonic dystrophy type 1, highlighting dose-dependent splicing correction from FREEDOM and FREEDOM2 trials. The company faces ongoing regulatory interactions including a partial FDA clinical hold on FREEDOM2, with data readout timelines and potential for functional improvements pending higher-dose treatment results.